RxDoctor Payments Data

Anthony Golio, MD

Urology · Pittsburgh, PANPI 1003879172

Payments from drug & device makers

$2,461in general payments, 2019–2025

Across 74 payments — averaging $33.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Astellas Pharma US Inc$550
  • Sumitomo Pharma America, Inc.$222
  • Pfizer$158
  • Johnson & Johnson$60
  • Neotract Inc.$51
  • plus $167 from 8 others

What the payments were for

  • Consulting fees$1,20049%
  • Food & beverage$96939%
  • Education$29212%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,461 in reported general payments places this provider in the 50th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,218
Medicare patients
133
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron48$26,845
GemtesaVibegron21$12,389
ElmironPentosan Polysulfate Sodium15$8,787
Finasteride358$4,825
Tamsulosin Hcl283$4,258
Solifenacin Succinate142$3,928
Potassium Citrate ErPotassium Citrate47$3,443
Tolterodine Tartrate ErTolterodine Tartrate25$3,126
Alfuzosin Hcl ErAlfuzosin Hcl92$2,171
Desmopressin Acetate18$1,801
Oxybutynin Chloride ErOxybutynin Chloride23$967
Trimethoprim26$888
Imipramine Hcl32$589
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst26$481
Methenamine Hippurate11$476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$550$26,84548 claims
Sumitomo Pharma America, Inc.Gemtesa$222$12,38921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 596 urology providers in Pennsylvania.

Other urology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →